ZP was delighted to give a talk at the Future of Blood Testing Network, on this page we have placed a copy of the slides given.
ZP: A Pioneering Player in the Future of Blood Testing
Welcome to this presentation on the future of blood testing, specifically on the role of ZP in translating cutting-edge scientific advancements into commercially viable products. I’m Dr. [Speaker’s Name], a chemist and electrochemist with extensive experience in the development and commercialization of medical diagnostic technologies.
Blood testing has evolved significantly over the years, from bulky laboratory instruments to handheld devices and wearables. Today, ZP stands at the forefront of this transformation, employing electrochemical biosensors to revolutionize blood testing.
ZP’s expertise in electrochemical biosensors lies in their versatility, enabling the detection of a wide range of analytes, including glucose, oxygen, lactate, histamine, and various hormones. This versatility makes electrochemical biosensors ideal for various applications, including point-of-care testing, wearable devices, and continuous glucose monitoring.
ZP’s platforms for developing and commercializing blood testing devices streamline the process, encompassing everything from assay development and hardware design to regulatory approval and commercialization. Our SensiAll platform, for instance, facilitates the rapid development of new assays, while our Julie cloud-based database system ensures seamless data management.
To illustrate ZP’s capabilities in wearable blood testing, let’s consider a case study of a company that developed a blood test for stroke: Sarissa. Sarissa’s goal was to differentiate between actual strokes and stroke mimics, a challenge that could significantly improve stroke treatment outcomes.
The Sarissa team faced numerous challenges, including the transient nature of the purine marker they were using, the difficulty of recruiting patients for clinical trials, and the financial constraints imposed by the global COVID-19 pandemic.
Despite these challenges, ZP acquired Sarissa‘s intellectual property and assets, leveraging our expertise and platforms to accelerate the development of the technology. We also implemented Lean Startup principles, focusing on rapid iteration and minimizing development time.
The lessons learned from the Sarissa journey underscore the importance of financial preparedness, careful assessment of market conditions, and the ability to pivot as needed. Fail fast, succeed fast is the essence of Lean Startup, enabling companies to adapt to changing market dynamics and capitalize on early successes.
ZP is committed to supporting the translation of academic research into commercially viable products, bridging the gap between the laboratory and the clinic. We believe that electrochemical biosensors, with their versatility and miniaturization, hold the key to transforming blood testing into a seamless, user-friendly experience.
If you are interested in learning more about ZP’s capabilities in commercializing academic research, please do not hesitate to contact us. Together, we can pave the way for a future where blood testing is accessible, affordable, and transformative for healthcare.